References
- Rajalakshmi R, Kumari R, Thappa DM. Acyclovir versus valacyclovir. Indian J Dermatol Venereol Leprol 2010;76:439–444.
- Arndt KA. Adverse reactions to acyclovir: topical, oral, and intravenous. J Am Acad Dermatol 1988;18:188–190.
- Le A, Patel S. Extravasation of noncytotoxic drugs: a review of the literature. Ann Pharmacother 2014;48:870–886.
- Sauerland C, Engelking C, Wickham R, Corbi D. Vesicant extravasation part I: mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 2006;33:1134–1141.
- Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Oncol 2003;14:iii26–iii30.
- Langstein HN, Duman H, Seelig D, et al. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 2002;49:369–374.
- Barbee MS, Owonikoko TK, Harvey RD. Taxanes: vesicants, irritants, or just irritating?. Ther Adv Med Oncol 2014;6:16–20.
- Sarica A. Bullous cutaneous eruption due to extravasation of acyclovir in an adolescent with acute lymphoblastic leukemia. Turk J Haematol 2012;29:109–110.
- Gurkan A, Erkek N, Senel S. Localized bullous eruptions away from infusion site due to intravenous acyclovir administration in a child. Indian J Pharmacol 2012;44:126–128.
- Armingaud P, Arsac P, Kerdraon R, Esteve E. Localized bullous eruption after intravenous injection of aciclovir: toxic or immunoallergic mechanism?. Ann Dermatol Venereol 2000;127:496–498.
- Buck ML, Vittone SB, Zaglul HF. Vesicular eruptions following acyclovir administration. Ann Pharmacother 1993;27:1458–1459.
- De Souza BA, Shibu M. Painless acyclovir extravasation injury in a diabetic. Br J Plast Surg 2002;55:264.